Clinical Trial Update: A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors [Phase 2]

View source ↗

Summary

This Phase 2 study of BL-B01D1 in combination with a PD-1 monoclonal antibody for recurrent or metastatic head and neck squamous cell carcinoma is currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• BL-B01D1
• PD-1 monoclonal antibody

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING